MMI (Medical Microinstruments, Inc.) raised $110 million in Series C financing.
Funds will support commercialization of the Symani Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
Symani represents a first-of-its-kind robotic technology that addresses the scale and complexities of microsurgery and supermicrosurgery. By allowing surgeons to replicate the natural movements of the human hand at the micro scale, it can expand treatment options for patients in need of soft tissue, open surgical procedures, such as free flap reconstructions and trauma replantations.
MMI has raised over $200 million in funding to date. In 2022, it closed a Series B financing round to propel growth. The funding was allocated to help expand indications and support ongoing commercialization efforts for the Symani Surgical System in Europe, where it received CE Mark in 2019, accelerate plans to commercialize in the U.S. and Asia-Pacific, and advance clinical research.
MMI (Medical Microinstruments, Inc.) raised $110 million in Series C financing.
Funds will support commercialization of the Symani Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and...
MMI (Medical Microinstruments, Inc.) raised $110 million in Series C financing.
Funds will support commercialization of the Symani Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
Symani represents a first-of-its-kind robotic technology that addresses the scale and complexities of microsurgery and supermicrosurgery. By allowing surgeons to replicate the natural movements of the human hand at the micro scale, it can expand treatment options for patients in need of soft tissue, open surgical procedures, such as free flap reconstructions and trauma replantations.
MMI has raised over $200 million in funding to date. In 2022, it closed a Series B financing round to propel growth. The funding was allocated to help expand indications and support ongoing commercialization efforts for the Symani Surgical System in Europe, where it received CE Mark in 2019, accelerate plans to commercialize in the U.S. and Asia-Pacific, and advance clinical research.
Copy to clipboard 
